Information:
Fel:
ID
28366
Beskrivning
Figitumumab Combined With Pegvisomant For Advanced Solid Tumors; ODM derived from: https://clinicaltrials.gov/show/NCT00976508
Länk
https://clinicaltrials.gov/show/NCT00976508
Nyckelord
Versioner (1)
- 2018-01-08 2018-01-08 -
Rättsinnehavare
See clinicaltrials.gov
Uppladdad den
8 januari 2018
DOI
För en begäran logga in.
Licens
Creative Commons BY 4.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Eligibility Colorectal Neoplasms NCT00976508
Eligibility Colorectal Neoplasms NCT00976508
- StudyEvent: Eligibility
Similar models
Eligibility Colorectal Neoplasms NCT00976508
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Age | Solid tumour Advanced | Treatment options Combined Modality Therapy | figitumumab | pegvisomant
Item
patients ≥18 years of age with advanced solid tumors for which the combination of figitumumab and pegvisomant are reasonable treatment options.
boolean
C0001779 (UMLS CUI [1])
C0280100 (UMLS CUI [2,1])
C0205179 (UMLS CUI [2,2])
C0683525 (UMLS CUI [3,1])
C0009429 (UMLS CUI [3,2])
C2713009 (UMLS CUI [4])
C0913469 (UMLS CUI [5])
C0280100 (UMLS CUI [2,1])
C0205179 (UMLS CUI [2,2])
C0683525 (UMLS CUI [3,1])
C0009429 (UMLS CUI [3,2])
C2713009 (UMLS CUI [4])
C0913469 (UMLS CUI [5])
Age | Sarcoma Advanced | Curative treatment Lacking | Therapeutic procedure Proven Lacking | Survival Problem | Quality of life Problem
Item
patients between the ages of 10 and 18 years with advanced sarcomas for which there is no available curative therapy or therapy proven to prolong survival with an acceptable quality of life will be included in the sarcoma expansion cohort.
boolean
C0001779 (UMLS CUI [1])
C1261473 (UMLS CUI [2,1])
C0205179 (UMLS CUI [2,2])
C1273390 (UMLS CUI [3,1])
C0332268 (UMLS CUI [3,2])
C0087111 (UMLS CUI [4,1])
C0456369 (UMLS CUI [4,2])
C0332268 (UMLS CUI [4,3])
C0038952 (UMLS CUI [5,1])
C0033213 (UMLS CUI [5,2])
C0034380 (UMLS CUI [6,1])
C0033213 (UMLS CUI [6,2])
C1261473 (UMLS CUI [2,1])
C0205179 (UMLS CUI [2,2])
C1273390 (UMLS CUI [3,1])
C0332268 (UMLS CUI [3,2])
C0087111 (UMLS CUI [4,1])
C0456369 (UMLS CUI [4,2])
C0332268 (UMLS CUI [4,3])
C0038952 (UMLS CUI [5,1])
C0033213 (UMLS CUI [5,2])
C0034380 (UMLS CUI [6,1])
C0033213 (UMLS CUI [6,2])
Prior Therapy | Patient recovered
Item
adequate recovery from prior therapies.
boolean
C1514463 (UMLS CUI [1])
C1115804 (UMLS CUI [2])
C1115804 (UMLS CUI [2])
Organ function | Bone Marrow function | Renal function | Liver function
Item
adequate organ function (i.e. bone marrow, kidney, liver)
boolean
C0678852 (UMLS CUI [1])
C0005953 (UMLS CUI [2,1])
C0031843 (UMLS CUI [2,2])
C0232804 (UMLS CUI [3])
C0232741 (UMLS CUI [4])
C0005953 (UMLS CUI [2,1])
C0031843 (UMLS CUI [2,2])
C0232804 (UMLS CUI [3])
C0232741 (UMLS CUI [4])
Insulin-Like Growth Factor I
Item
total igf-1 ≥100 ng/ml (13 nmol/l).
boolean
C0021665 (UMLS CUI [1])
Antineoplastic Agents
Item
concurrent treatment with any anti-tumor agents.
boolean
C0003392 (UMLS CUI [1])
Pregnancy | Breast Feeding
Item
pregnant or breastfeeding females.
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C0006147 (UMLS CUI [2])
Heart Disease
Item
significant past history or active cardiac disease
boolean
C0018799 (UMLS CUI [1])
Communicable Disease
Item
active infection
boolean
C0009450 (UMLS CUI [1])
Diabetes Mellitus
Item
history of diabetes mellitus.
boolean
C0011849 (UMLS CUI [1])
Glycosylated hemoglobin measurement
Item
glycosylated hemoglobin >5.7
boolean
C0202054 (UMLS CUI [1])